TRDMT1 and ovarian carcinoma: Indeed, we observed enhanced sensitivities of cells treated with siTRDMT1 to cisplatin in multiple cell lines including U2OS, breast cancer cell line MCF-7 and ovarian cancer cell line SKOV3 (Figure 1A), confirming that downregulation of TRDMT1 increases the sensitivity of tumor cells to Cisplatin.